

## **Referències bibliogràfiques**

Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. *Pediatr Infect Dis J* 2003, 22: 782-788.

Amaudo E, Dalakas M, Shanske S, Moraes CT, DiMeuro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. *Lancet* 1991, 337: 508-510.

Amaya R, Kozinetz C, McMeans A, Schwarzwald H, Kline M. Lipodystrophy syndrome in human immunodeficiency virus-infected children. *Pediatr Infect Dis J* 2002, 21: 405-410.

Andersen O, Haugaard SB, Jorgensen LT, Sorensen S, Nielsen JO, Madsbad S, *et al.* Preanalytical handling of samples for measurement of plasma lactate in HIV patients. *Scand J Clin Lab Invest* 2003, 63: 449-454.

Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, *et al.* Sequence and organization of the human mitochondrial genome. *Nature* 1981, 290: 457-465.

Arici C, Tebaldi A, Quinzan GP, Maggiolo F, Ripamonti D, Suter F. Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. *Int J STD AIDS* 2001, 12: 407-409.

Artuch R, Vilaseca MA, Farre C, Ramon F. Determination of lactate, pyruvate, beta-hydroxybutyrate and acetoacetate with a centrifugal analyser. *Eur J Clin Chem Biochem* 1995, 33: 529-533.

Artuch R, Colome C, Vilaseca MA, Pineda M, Campistol J. Ubiquinona: su metabolismo y funciones. Déficit de ubiquinona y su implicación en las encefalomiopatías mitocondriales. Tratamiento con ubiquinona. *Rev Neurol* 1999, 29: 59-63.

Artuch R, Pineda M, Vilaseca MA, Briones P, Ribes A, Colomer J, *et al.* Deficiencias de la cadena respiratoria y del metabolismo del piruvato en pacientes pediátricos: evaluación de las pruebas bioquímicas de selección. *Rev Neurol* 1998, 26: 38-42.

Barile M, Valenti D, Passarella S, Quagliariello E. 3'-Azido-3'-deoxythymidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator. *Biochem Pharmacol* 1997, 53: 913-920.

Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, *et al.* Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science* 1983, 220: 868-871.

Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, *et al.* Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. *AIDS* 2003, 17: 1769-1785.

Benbrik E, Chariot P, Bonavaud S, Ammi-Said M, Frisdal E, Rey C, *et al.* Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. *J Neurol Sci* 1997, 149: 19-25.

Birkus G, Hajek M, Kramata P, Votruba I, Holy A, Otova B. Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon. *Antimicrob Agents Chemother* 2002, 46: 1610-1613.

Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier M, *et al.* Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. *J Intern Med* 1994, 235: 367-371.

Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, *et al.* Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. *Lancet* 1999, 354: 1084-1089.

Bobat R, Coovadia H, Moodley D, Coutsoodis A, Gouws E. Growth in early childhood in a cohort of children born to HIV-1-infected women from Durban, South Africa. *Ann Trop Paediatr* 2001, 21: 203-210.

Bockhorst JL, Ksseiry I, Toye M, Chipkin SR, Stechenberg BW, Fisher DJ, *et al.* Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. *Pediatr Infect Dis J* 2003, 22: 463-465.

Boffito M, Marietti G, Audagnotto S, Raiter R, Di Perri G. Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors. *Clin Infect Dis* 2002, 34: 558.

Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, *et al.* Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. *Clin Infect Dis* 2001, 33: 1931-1937.

Bouhours-Nouet N, May-Panloup P, Coutant R, de Casson FB, Descamps P, Douay O, *et al.* Maternal smoking is associated with mitochondrial DNA depletion and respiratory chain complex III deficiency in placenta. *Am J Physiol Endocrinol Metab* 2005, 288: E171-E177.

Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. *AIDS* 1998; 12: 1735-1744.

Brinkman K, ter Hofstede HJ. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. *AIDS Rev* 1999, 1: 141-148.

Brinkman K. Editorial response: hyperlactataemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. *Clin Infect Dis* 2000, 31: 167-169.

Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. *AIDS* 2001, 15: 795-797.

Bristol-Myers Squibb Company. Healthcare provider important drug warning letter. 5 January 2001.

Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Farley J, Lampe M, *et al.* Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. *Ann N Y Acad Sci* 2000, 918: 212-221.

Butler KM, Husson RN, Balis FM, Brouwers P, Eddy J, el-Amin D, *et al.* Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. *N Engl J Med* 1991, 324: 137-144.

Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. *Lancet* 1999, 353: 2093-2099.

Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidosis and lower weight pre-antiretroviral therapy. *AIDS* 2001, 15: 703-709.

Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, *et al.* Abacavir substitution for nucleoside analogs in patients with HIV lipodystrophy: a randomized trial. *JAMA* 2002, 288: 207-215.

Castedo M, Perfettini JL, Andreau K, Roumier T, Piacentini M, Kroemer G. Mitochondrial apoptosis induced by the HIV-1 envelope. *Ann N Y Acad Sci* 2003, 1010: 19-28.

Centers for Disease Control and Prevention. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. *MMWR* 1987, 36: 1-15.

Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR* 1994, 13: 1-10.

Chariot P, Ratiney R, Ammi-Said M, Herigault R, Adnot S, Gherardi R. Optimal handling of blood samples for routine measurement of lactate and pyruvate. *Arch Pathol Lab Med* 1994, 118: 695-697.

Chariot P, Gherardi R. Myopathy and HIV infection. *Curr Opin Rheumatol* 1995, 7: 497-502.

Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, *et al.* Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. *J Hepatol* 1999, 30: 156-160.

Chattha G, Arieff AI, Cummings C, Tierney LM. Lactic acidosis complicating acquired immunodeficiency syndrome. *Ann Intern Med* 1993, 118: 37-39.

Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. *J Biol Chem* 1989, 264: 11934-11937.

Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. *Mol Pharmacol* 1991, 39: 625-628.

Cherrington JM, Allen SJ, McKee BH, Chen MS. Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma. *Biochem Pharmacol* 1994, 48:1986-1988.

Church JA, Mitchell WG, Gonzalez-Gomez I, Christensen J, Vu TH, DiMauro S, *et al.* Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. *J Pediatr* 2001, 138: 748-751.

Church JA. Reversible leukoencephalopathy in a patient with nucleoside analogue-associated mitochondrial DNA depletion and metabolic disease. *AIDS* 2002, 16: 2366-2367.

Claessens YE, Cariou A, Monchi M, Soufir L, Azoulay E, Rouges P, *et al.* Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. *Crit Care Med* 2003, 31 : 1042-1047.

Cobo J, Ruiz MF, Figueroa MS, Antela A, Quereda C, Perez-Elias MJ, *et al.* Retinal toxicity associated with didanosine in HIV-infected adults. *AIDS* 1996, 10:1297-1300.

Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. *Clin Infect Dis* 2001, 33: 1914-1921.

Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, *et al.* Reduction of maternal-infant transmission of human immunodeficiency virus type-1 with zidovudine treatment. *N Engl J Med* 1994, 331: 1173-1180.

Cossarizza A, Ortolani C, Mussini C, Borghi V, Guaraldi G, Mongiardo N, *et al.* Massive activation of immune cells with an intact T cell repertoire in acute human immunodeficiency virus syndrome. *J Infect Dis* 1995, 172: 105-112.

Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. *AIDS* 2004, 18: 137-151.

Côté HCF, Brumme ZL, Craib JKP, Alexander CS, Wynhoven B, Ting L, *et al.* Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. *New Engl J Med* 2002, 346: 811-820.

Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell, *et al.* Lack of long-term effects among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. *JAMA* 1999, 281: 151-157.

Dagan T, Sable C, Bray J, Gerschenson M. Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence? *Mitochondrion* 2002, 1: 397-412.

Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. *N Engl J Med* 1990, 322: 1098-1105.

Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, *et al.* 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. *Antimicrob Agents Chemother* 1997, 41: 1082-1093.

Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. *Ann Neurol* 2001, 49: 377-383.

Desai N, Mathur M, Weedon J. Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy. *AIDS* 2003, 17: 1565-1568.

De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. *Arch Intern Med* 2002, 162: 355.

Dimauro S, Bonilla E, De Vivo DC. Does the patient have a mitochondrial encephalomyopathy? *J Child Neurol* 1999, 14: S23-S35.

DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. *N Engl J Med* 2003, 348: 2656-2668.

Divi RL, Walker VE, Wade NA, Nagashima K, Seilkop SK, Adams ME, *et al.* Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. *AIDS* 2004, 18: 1013-1021.

Domanski MJ, Sloas MM, Follmann DA, Scalise PP 3rd, Tucker EE, Egan D, *et al.* Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. *J Pediatr* 1995, 127: 137-146.

Dominguez K, Bertolli J, Fowler M, Peters V, Ortiz I, Melville S, *et al.* Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children  $\leq 5$  years of age, Pediatric Spectrum of HIV Disease Project (PSD), USA. *Ann N Y Acad Sci* 2000, 918: 236-246.

Dunn DT, Brandt CD, Krivine A, Cassol SA, Roques P, Borkowsky W, *et al.* The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. *AIDS* 1995, 9: F7-11.

Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. HIV Paediatric Prognostic Markers Collaborative Study Group. *Lancet* 2003, 362: 1605-1611.

ESS40010 (TARHEEL) Study Team. Lack of Recurrence of Hyperlactatemia in HIV-Infected Patients Switched From Stavudine to Abacavir or Zidovudine. *J Acquir Immune Defic Syndr* 2004, 36: 935-942.

European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. *J Acquir Immun Defic Syndr* 2003, 32: 380-387.

Ewings EL, Gerschenson M, St Claire MC, Nagashima K, Skopets B, Harbaugh SW, *et al.* Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria. *J Acquir Immune Def Syndr* 2000, 24: 100-105.

Falco V, Rodriguez D, Ribera E, Martinez E, Miro JM, Domingo P, *et al.* Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. *Clin Infect Dis* 2002, 34: 838-846.

Farley J, Gona P, Crain M, Cervia J, Lindsey J, Oleske J. Prevalence of hypercholesterolemia and associated risk factors among perinatally HIV-infected children (4-19 years) in PACTG 219C. 10<sup>th</sup> Conference on Retroviruses and Opportunistic Infections; Boston, February 2003 (abstract 773).

Faulds D, Brogden RN. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. *Drugs* 1992, 44: 94-116.

Faye A, Bertone C, Teglas JP, Chaix ML, Douard D, Firtion G, *et al.* Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. *Pediatr Infect Dis J* 2002, 21: 518-525.

Food and Drug Administration. FDA Public Health Advisory: reports of diabetes and hyperglycemia in patients receiving protease inhibitors for treatment of human immunodeficiency virus (HIV). Food and Drug Administration, Public Health Service, Department of Health and Human Services. Rockville, MD: June 11, 1997.

Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. *Am J Gastroenterol* 1995, 90: 1433-1436.

Fouty B, Frerman F, Reves R. Riboflavin to treat NRTI induced lactic acidosis. *Lancet* 1998, 352: 291- 292.

Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. *AIDS* 1993, 7: 379-385.

Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. *AIDS* 2002, 16: 299-300.

Gerard Y, Maulin L, Yazdanpanah Y, De La Tribonniere X, Amiel C, Maurage CA, *et al.* Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. *AIDS* 2000, 14: 2723-2730.

Gerschenson M, Erhart SW, Paik CY, St Claire MC, Nagashima K, Skopets B, *et al.* Fetal mitochondrial heart and muscle damage in *Erythrocebus patas* monkeys exposed *in utero* to 3'-azido-3'-deoxythymidine (AZT). *AIDS Res Hum Retroviruses* 2000, 16: 635-644.

Gerschenson M, Nguyen V, Ewings EL, Ceresa A, Shaw JA, St Claire MC, *et al.* Mitochondrial toxicity in fetal *Erythrocebus patas* monkeys exposed transplacentally to zidovudine plus lamivudine. *AIDS Res Hum Retroviruses* 2004, 20: 91-100.

Giaquinto C, De Romeo A, Giacomet V, Rampon O, Ruga E, Burlina A, *et al.* Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. *AIDS* 2001, 15: 1074-1075.

Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, *et al.* Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. *BMJ* 2003, 327: 1019.

Gold R, Meurers B, Reichmann H. Mitochondrial myopathy caused by long-term zidovudine therapy. *N Engl J Med* 1990, 323: 994.

Gottlieb MS. AIDS – past and future. *N Engl J Med* 2001, 344: 1788-1791.

Gray L, Newell ML, Thorne C, Peckham C, Levy J. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. European Collaborative Study. *Pediatrics* 2001, 108: 116-122.

Grimbert S, Fromenty B, Fisch C, Letteron P, Berson A, Durand-Schneider AM, *et al.* Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy. *Hepatology* 1993, 17: 628-637.

Guyton AC. Capítulo 67. Metabolismo de los carbohidratos y formación de adenosintrifosfato. En: *Tratado de Fisiología Médica*, 8ª Edición. Editorial Interamericana-McGraw-Hill. Páginas 780-789.

Haas RH. A comparison of genetic mitochondrial disease and nucleoside analogue toxicity. Does fetal nucleoside toxicity underlie reports of mitochondrial disease in infants born to women treated for HIV infection? *Ann N Y Acad Sci* 2000, 918: 247-261.

Hainaut M, Peltier CA, Gerard M, Marissens D, Zissis G, Levy J. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1. *Europ J Pediatr* 2000, 159: 778-782.

Hart GJ, Orr DC, Penn CR, Figueiredo HT, Gray NM, Boehme RE, *et al.* Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. *Antimicrob Agents Chemother* 1992, 36: 1688-1694.

Hayes EV, McGann KA. Complications of human immunodeficiency virus therapy. *Pediatr Infect Dis J* 2004, 23: 873-874.

HIV Neuromuscular Syndrome Study Group. HIV-associated neuromuscular weakness syndrome. *AIDS* 2004, 18: 1403-1412.

Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. *Int J STD AIDS* 2000, 11: 611-616.

Huang P, Farquhar D, Plunkett W. Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. *J Biol Chem* 1992, 267: 2817-2822.

Huynh TK, Luttichau HR, Roge BT, Gerstoff J. Natural history of hyperlactataemia in human immunodeficiency virus-1-infected patients during highly active antiretroviral therapy. *Scand J Infect Dis* 2003, 35: 62-66.

Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HL, Zamzami N, *et al.* The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. *J Exp Med* 2000, 19: 33-46.

James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovir-related nephrotoxicity: case report and review of the literature. *Pharmacotherapy* 2004, 24: 415-418.

Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, *et al.* Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. *AIDS* 2000, 14: 2123-2128.

John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, *et al.* Chronic hyperlactatemia in HIV infected patients on antiretroviral therapy. *AIDS* 2001, 6: 717-723.

John M, Mallal S. Hyperlactataemia syndromes in people with HIV infection. *Curr Opin Infect Dis* 2002, 15: 23-39.

Johns DR. The other human genome: mitochondrial DNA and disease. *Nat Med* 1996, 2: 1065-1068.

Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, *et al.* Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. *JAMA* 1999, 282: 2305-2312.

Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. *AIDS* 1999, 13: 2311-2312.

Kakuda T, Brinkman K. Mitochondrial toxic effects and ribavirin. *Lancet* 2001, 357: 1802-1803.

Kinoshita K, Maeda E, Yoshida S. The measurement of blood lactate concentration and its age change in days on healthy infant. *Jpn J Clin Pathol* 1995, 43: 1071-1076.

Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, McKinney RE Jr, *et al.* A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. *Pediatrics* 1998, 101:214-220.

Knight-Lozano CA, Young CG, Burow DL, Hu ZY, Uyeminami D, Pinkerton KE, *et al.* Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. *Circulation* 2002, 105: 849-854.

Koren G, Pastuszak A, Itos S. Drugs in pregnancy. *N Engl J Med* 1998, 338: 1128-1137.

Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). *Ann Intern Med* 1991, 115: 283-284.

Landreau-Mascaro A, Barret B, Mayaux MJ, Tardieu M, Blanche S. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. *Lancet* 2002, 359: 583-584.

Laue L, Pizzo PA, Butler K, Cutler GB. Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome. *J Pediatr* 1990, 117: 541-545.

Leonard JV, Schapira AHV. Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. *Lancet* 2000, 355: 299-304.

Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. *Pediatr Infect Dis J* 2003, 22: 77-84.

Leroy V, Newell ML, Dabis F, Peckham C, Van de Perre P, Bulterys M, *et al.* International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-to-Child Transmission of HIV. *Lancet* 1998, 352: 597-600.

Lewis LL, Venzon D, Church J, Farley M, Wheeler S, Keller A, *et al.* Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. *J Infect Dis* 1996, 174: 16-25.

Lewis LD, Strawbridge RR, McQuilkin SHA. Potential intracellular target for 2',3'-dideoxyinosine (ddI) related pancreatic toxicity [abstract]. *Clin Pharmacol Ther* 1998, 63: 180.

Lewis W, Copeland WC, Day BJ. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. *Lab Invest* 2001, 6: 777-790.

Lindegren ML, Rhodes P, Gordon L, Fleming P. Drug safety during pregnancy and in infants: lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. *Ann N Y Acad Sci* 2000, 918: 222-235.

Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. *Clin Infect Dis* 2000, 31: 162-166.

Lonergan JT, Barber RE, Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. *AIDS* 2003, 21: 2495-2499.

Lozano F, Ramayo E, Corzo JE, Gómez-Mateos J. Hiperlactatemia sintomática en pacientes con infección por el virus de la inmunodeficiencia humana tratados con análogos de nucleósidos. *Med Clin (Barc)* 2001, 117: 36.

Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, *et al.* Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. *N Engl J Med* 1997, 336: 1343-1349.

Luzuriaga K, McManus M, Catalina M, Mayack S, Sharkey M, Stevenson M, *et al.* Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. *J Virol* 2000, 74: 6984-6991.

Luzzatti R, Del Bravo P, Di Perri G, Luzzani A, Concia E. Riboflavin and severe lactic acidosis. *Lancet* 1999, 353: 901-902.

Madias N. Lactic acidosis. *Kidney Int* 1986, 29: 752-774.

Mandelbrot L, Kermarrec N, Marcollet A, Lafanechere A, Longuet P, Chosidow D, *et al.* Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. *AIDS* 2003, 17: 272-273.

Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, *et al.* Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. *AIDS* 2001, 15: 1261-1268.

Mayaux MJ, Burgard M, Teglas JP, *et al.* Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. The French Pediatric HIV Infection Study Group. *JAMA* 1996, 275: 606-610.



McKinney RE Jr, Maha MA, Connor EM, Feinberg J, Scott GB, Wulfsohn M, *et al.* A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. *N Engl J Med* 1991, 324: 1018-1025.

McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, *et al.* A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naïve HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. *J Pediatr* 1998, 133: 500-508.

McLeod GX, Hammer SM. Zidovudine: five years later. *Ann Intern Med* 1992, 117: 487-501.

Medina DJ, Tsai CH, Hsiung GD, Cheng YC. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. *Antimicrob Agents Chemother* 1994, 38: 1824-1828.

MMRW. *Pneumocystis pneumonia* – Los Angeles. *MMWR Morb Mortal Wkly Rep* 1981, 30: 250-252.

MMRW. Unexplained immunodeficiency and opportunistic infections in infants – New York, New Jersey, California. *MMWR Morb Mort Wkly Rep* 1982, 31: 665-667.

Mofenson LM, Korelitz J, Meyer WA 3rd, Bethel J, Rich K, Pahwa S, *et al.* The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. *J Infect Dis* 1997, 175: 1029-1038.

Mofenson LM. Advances in the prevention of vertical transmission of human immunodeficiency virus. *Semin Pediatr Infect Dis* 2003, 14: 295-308.

Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. *Clin Infect Dis* 2000, 30: 198-200.

Montaner JS, Cote HC, Harris M, Hogg RS, Yip B, Chan JW, *et al.* Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. *J Acquir Immune Defic Syndr* 2003, 34: S85-S90.

Montaner JS, Cote HC, Harris M, Hogg RS, Yip B, Harrigan PR, *et al.* Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. *Clin Infect Dis* 2004, 38: S73-S79.

Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Vignano A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. *J Clin Endocrinol Metab* 2004, 89: 24-28.

Moreno A, Quereda C, Moreno L, Perez-Elias MJ, Muriel A, Casado JL, *et al.* High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. *Antivir Ther* 2004, 9: 133-138.

Moretti S, Famularo G, Marcellini S, Boschini A, Santini G, Trinchieri V, *et al.* L-carnitine reduces lymphocyte apoptosis and oxidative stress in HIV-1-infected subjects treated with zidovudine and didanosine. *Antioxid Redox Signal* 2002, 4: 391-403.

Morgello S, Wolfe D, Gadjrey E, Feinstein R, Tagliati M, Simpson DM. Mitochondrial abnormalities in human immunodeficiency virus-associated myopathy. *Acta Neuropathol* 1995, 90: 366-374.

Morris AAM, Leonard JV. Treatment of congenital lactic acidosis. *J Inher Metab Dis* 1996, 19: 573-580.

Moyano D, Vilaseca MA, Artuch R, Lambruschini N. Plasma amino acids in anorexia nervosa. *Eur J Clin Nutr* 1998, 52: 684-689.

Moyle GJ. Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism? *Drug Saf* 2000, 23: 467-481.

Moyle GJ. Hyperlactatemia and lactic acidosis. Should routine screening be considered? *AIDS Read* 2002, 12: 344-348.

Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproductibility and possible risk factors. *AIDS* 2002, 16: 1341-1349.

Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, *et al.* Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. *JAMA* 2000, 283: 492-498.

Nguyen BY, Yarchoan R, Wyvill KM, Venzon DJ, Pluda JM, Mitsuya H, *et al.* Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection. *J Infect Dis* 1995, 171: 1180-1189.

Nie Z, Phenix BN, Lum JJ, Alam A, Lynch DH, Beckett B, *et al.* HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. *Cell Death Differ* 2002, 9: 1172-1184.

Nielsen J, Ytrebo LM, Borud O. Lactate and pyruvate concentrations in capillary blood from newborns. *Acta Paediatr* 1994, 920-922.

Noguera A, Fortuny C, Sanchez E, Artuch R, Vilaseca MA, Muñoz-Almagro C, *et al.* Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. *Pediatr Infect Dis J* 2003, 22: 778-782.

Noguera A, Fortuny C, Muñoz-Almagro C, Sanchez E, Vilaseca MA, Artuch R, *et al.* Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. *Pediatrics* 2004, 114: e598-603.

Ogedegbe AEO, Thomas DL, Diehl AM. Hyperlactatemia syndromes associated with HIV therapy. *Lancet Infect Dis* 2003, 3: 329-337.

Olivero OA, Fernandez JJ, Antiochos BB, Wagner JL, St Claire ME, Poirier MC. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in *Erythrocebus patas* monkeys. *J Acquir Def Syndr* 2002, 29: 323-329.

Paediatric European Network for Treatment of AIDS. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. *AIDS* 1998, 12: F151-160.

Painter G, St Clair M, Ching S, Noblin J, Wang L, Furman PA. 524W91. Drugs of the future 1995, 20: 761.

Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA, *et al.* Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. *JAMA* 1998, 279: 756-761.

Pan-Zhou XR, Cui L, Zhou XJ, Sommadossi JP, Darley-Usmar VM. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. *Antimicrob Agents Chemother* 2000, 44: 496-503.

Patterson TA, Binienda ZK, Lipe GW, Gillam MP, Slikker W Jr, Sandberg JA. Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late-term rhesus macaques after maternal infusion. *Drug Metab Dispos* 1997, 25: 453-459.

PETRA Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, And Uganda (PETRA Study): a randomised, double-blind, placebo-controlled trial. *Lancet* 2002, 359: 1178-1186.

Poirier MC, Divi RL, Al-Harhi L, Olivero OA, Nguyen V, Walker B, *et al.* Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. *J Acquir Immune Defic Syndr* 2003, 33: 175-183.

Polster BM, Fiskum G. Mitochondrial mechanisms of neural cell apoptosis. *J Neurochem* 2004 90: 1281-1289.

Public Health Service Task Force. Guidelines for the use of antiretroviral agents in Pediatric HIV Infection. Available at: <http://www.hivatis.org>. Accessed 20 January 2004.

Public Health Service Task Force. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: <http://www.hivatis.org>. Accessed 23 March 2004.

Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Available at: <http://www.hivatis.org>. Accessed 23 June 2004.

Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, *et al.* Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. *AIDS* 2000, 14: 51-57.

Raidel SM, Haase C, Jansen NR, Russ RB, Sutliff RL, Velsor LW, *et al.* Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. *Am J Physiol Heart Circ Physiol* 2002, 282: H1672-H1678.

Reid RA, Moyle J, Mitchell P. Synthesis of adenosine triphosphate by a protonmotive force in rat liver mitochondria. *Nature* 1966, 212: 257-258.

Resino S, Bellon JM, Resino R, Navarro ML, Tomas Ramos J, de Jose MI, *et al.* Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-infected children. *Clin Infect Dis* 2004, 38:1605-1612.

Rey C, Prieto S, Medina A, Perez C, Concha A, Menendez S. Fatal lactic acidosis during antiretroviral therapy. *Pediatr Crit Care Med* 2003, 4: 485-487.

Rosso R, DiBiagio A, Ferrazin A, Bassetti M, Ciravegna BW, Bassetti D, *et al.* Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection. *Pediatr Infect Dis J* 2003, 22 : 668-670.

Saint-Marc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. *AIDS* 1999, 13: 2188-2189.

Sanchez DJ, Murphy MM, Bosch-Sabater J, Fernandez-Ballard J. Enzymatic evolution of thiamin, riboflavin and piridoxine status of parturient mothers and their newborn infants in a Mediterranean area of Spain. *Eur J Clin Nutr* 1999, 53: 27-38.

Sanchez JM, Ramos Amador JT, Fernandez de Miguel S, Gonzalez Tomee MI, Rojo Conejo P, Ferrando Vivas P, *et al.* Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. *Pediatr Infect Dis J* 2003, 22: 863-867.

Sarner L, Fakoya A. Acute lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. *Sex Transm Inf* 2002, 78: 58-59.

Scalfaro P, Chesaux JJ, Buchwalder PA, Biollaz J, Micheli JL. Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. *Intensive Care Med* 1998, 24: 247-250.

Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, *et al.* Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. *J Acquir Immun Defic Syndr* 2002, 31: 257-275.

Sepkowitz KA. AIDS – the first 20 years. *N Engl J Med* 344, 23: 1764-1772.

Shaer AJ, Rastegar A. Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome. A case report and review of the literature. *Am J Nephrol* 2000, 20: 332-338.

Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM. PENTA guidelines for the use of antiretroviral therapy, 2004. *HIV Medicine* 2004, 5: 61-86.

Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, *et al.* Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. *AIDS* 2001, 15: 1801-1809.

Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinti M, *et al.* Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. *J Acquir Immune Defic Syndr* 2003, 32: 370-374.

Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. *J Acquir Immune Defic Syndr Hum Retrovirol* 1995, 9: 153-161.

Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, *et al.* Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. *N Engl J Med* 1999, 341: 1874-1881.

Steinbrook R. Providing antiretroviral therapy for HIV infection. *N Engl J Med* 2001, 344: 844-846.

Taanman JW. The human mitochondrial genome: structure, transcription, translation and replication. *Biochim Biophys Acta* 1999, 1410: 103-123.

Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, *et al.* Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. *AIDS* 2000, 14: F63-67.

The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 – a meta-analysis of 15 prospective cohort studies. *N Engl J Med* 1999, 340: 977-987.

The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. *J Acquir Immune Defic Syndr* 2000, 25: 261-268.

Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, *et al.* Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. *Clin Infect Dis* 2000, 31: 1482-1487.

Thorne C, Newell ML. Prevention of mother-to-child transmission of HIV infection. *Curr Opin Infect Dis* 2004, 17: 247-252.

UNAIDS/04.45E. 2004 Report on the global AIDS epidemic: 4<sup>th</sup> global report. UNAIDS, December 2004.

Uusimaa J, Remes AM, Rantala H, Vainionpaa L, Herva R, Vuopala K, *et al.* Childhood encephalopathies and myopathies: a prospective study in a defined population to assess the frequency of mitochondrial disorders. *Pediatrics* 2000, 105: 598-603.

Valanne L, Ketonen L, Majander A, Suomalainen A, Pihko H. Neuroradiologic findings in children with mitochondrial disorders. *Am J Neuroradiol* 1998, 19: 369-377.

Van Den Berg J, Yerushalmy J. Studies on convulsive disorders in young children. Incidence of febrile and non febrile convulsions by age and other factors. *Pediatr Res* 1969, 3: 298-304.

Verma A, Schein RM, Jayaweera DT, Kett DH. Fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy. *Neurology* 1999, 53: 1365-1367.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. *Pediatrics* 2002, 109: E25.

Vir S, Love A, Thompson W. Riboflavin status during pregnancy. *Am J Clin Nutr* 1981, 34: 2699-2705.

Vrouenraets SME, Treskes M, Regez RM, Troost N, Weigel HM, Frissen PHJ, *et al.* Hyperlactatemia in HIV-infected patients: the role of NRTI treatment. 8<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 4-8 Feb 2001; abstract 625.

Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. *AIDS* 2002, 16: 2165-2173.

Wallace DC. Diseases of the mitochondrial DNA. *Annu Rev Biochem* 1992, 61: 1175-1212.

Wallace DC. Mitochondrial diseases in man and mouse. *Science* 1999, 283: 442-450.

Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, *et al.* Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. *AIDS* 1998, 12: F167-173.

Ward HA, Russo GG, Shrum J. Cutaneous manifestations of antiretroviral therapy. *J Am Acad Dermatol* 2002, 46: 284-293.

Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. *Pediatr Infect Dis J* 1999, 18: 682-869.

Wedekind CA, Pugatch D. Lipodystrophy syndrome in children infected with human immunodeficiency virus. *Pharmacotherapy* 2001, 21: 861-866.

Whitcup SM, Butler KM, Caruso R, de Smet MD, Rubin B, Husson RN, *et al.* Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine. *Am J Ophthalmol* 1992, 113:1-7.

White AJ. Mitochondrial toxicity and HIV therapy. *Sex Transm Inf* 2001, 77: 158-173.

White DJ, Mital D, Taylor S, St John JC. Sperm mitochondrial DNA deletions as a consequence of long term highly active antiretroviral therapy. *AIDS* 2001, 15: 1061-1062.

Wiznia A, Stanley K, Krogstad P, Johnson G, Lee S, McNamara J, *et al.* Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. *AIDS Res Hum Retroviruses* 2000, 16: 1113-1121.

Woo GH, Katayama K, Jung JY, Uetsuka K, Bak EJ, Nakayama H, *et al.* Hydroxyurea (HU)-induced apoptosis in the mouse fetal tissues. *Histol Histopathol* 2003, 18: 387-392.

Wooltorton E. HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome. *Can Med Assoc* 2002, 166: 1067-1068.

Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy. *Drugs* 2000, 59: 1251-1260.

Yang Z, Knight CA, Mamerow MM, Vickers K, Penn A, Postlethwait EM, *et al.* Prenatal Environmental Tobacco Smoke Exposure Promotes Adult Atherogenesis and Mitochondrial Damage in Apolipoprotein E-/- Mice Fed a Chow Diet. *Circulation* 2004, 110: 3715-3720.

Yogev R, Lee S, Wiznia A, Nachman S, Stanley K, Pelton S, *et al.* Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. *Pediatr Infect Dis J* 2002, 21: 119-125.